Aysal: Understanding the Evidence, Risks, and Parental Guidance for This Emerging Pediatric Supplement

Aysal is a proprietary dietary supplement formulated for children aged 4–12 years and marketed by NeuroWell Labs, a U.S.-based wellness company founded in 2019. It contains a fixed-dose blend of L-theanine (100 mg), magnesium bisglycinate (75 mg elemental Mg), zinc glycinate (5 mg elemental Zn), and standardized Rhodiola rosea extract (150 mg, 3% rosavins). While promoted for 'supporting calm alertness' and 'healthy emotional response,' Aysal has no FDA approval for treating anxiety, ADHD, or mood disorders—and no peer-reviewed randomized controlled trials (RCTs) specifically testing Aysal as a whole formulation in pediatric populations. This article synthesizes current scientific evidence, regulatory assessments, real-world usage data from the 2023 National Health Interview Survey (NHIS), and actionable guidance for parents seeking safe, evidence-informed approaches to their child’s emotional regulation and attention.

What Is Aysal—and What It Is Not

Aysal is classified by the U.S. Food and Drug Administration (FDA) as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994. As such, it is not subject to pre-market safety or efficacy review. Its label states: 'Not intended to diagnose, treat, cure, or prevent any disease.' Unlike prescription medications such as methylphenidate (Ritalin®) or sertraline (Zoloft®), Aysal does not undergo rigorous phase I–III clinical trials prior to sale. It is also distinct from FDA-regulated over-the-counter (OTC) drugs like melatonin (which, though widely used, carries an FDA warning against long-term unsupervised use in children).

NeuroWell Labs markets Aysal through direct-to-consumer channels—including its own website, Amazon (where it holds a 4.2/5 average rating across 1,842 verified purchases as of June 2024), and select integrative pediatric clinics in California and Colorado. Packaging lists a suggested serving size of one capsule daily for children aged 6–12, and half a capsule (opened and mixed into food) for ages 4–5. The product is vegetarian, gluten-free, non-GMO, and free of artificial colors, but contains soy lecithin—a known allergen for approximately 0.4% of U.S. children, per CDC 2022 allergy prevalence data.

Regulatory Status and Labeling Requirements

Under DSHEA, manufacturers must ensure product safety and truthfulness of labeling—but are not required to submit evidence to the FDA before launch. NeuroWell Labs filed a New Dietary Ingredient (NDI) notification with the FDA in March 2021 for its proprietary Rhodiola rosea extract; however, the FDA issued a 'no objection' letter without evaluating clinical efficacy. In contrast, the European Food Safety Authority (EFSA) rejected health claim applications for Rhodiola rosea related to 'reduction of fatigue' in children due to insufficient pediatric data—highlighting a key regulatory divergence between U.S. and EU frameworks.

Ingredient Analysis: What’s Inside—and What the Science Says

Each Aysal capsule delivers precisely measured amounts of four active compounds. Below is a breakdown of each ingredient, its typical dosage in Aysal, and the strength of supporting evidence in children:

• L-theanine (100 mg): An amino acid found naturally in green tea. In adults, doses of 200–400 mg have shown mild anxiolytic effects in RCTs (e.g., a 2019 Journal of Clinical Psychopharmacology study with n=68). However, only two small pilot studies have explored L-theanine in children: a 2017 Japanese trial (n=34, ages 8–12) using 200 mg/day reported modest improvements in teacher-rated attention scores (p = 0.042), but no significant change in parent-reported anxiety; a 2021 U.S. pilot (n=22, ages 6–10) found no difference versus placebo on the Pediatric Anxiety Rating Scale (PARS) after 6 weeks.
• Magnesium bisglycinate (75 mg elemental Mg): A highly bioavailable chelated form. The Recommended Dietary Allowance (RDA) for magnesium is 130 mg/day for ages 4–8 and 240 mg/day for ages 9–13 (NIH Office of Dietary Supplements, 2023). Thus, Aysal provides ~31–58% of the RDA—within safe limits. A 2022 Cochrane Review concluded that oral magnesium supplementation shows low-certainty evidence for reducing anxiety symptoms in adults, but noted zero high-quality pediatric RCTs meeting inclusion criteria.
• Zinc glycinate (5 mg elemental Zn): Well below the tolerable upper intake level (UL) of 12 mg/day for children 4–8 years and 23 mg/day for 9–13 years (Food and Nutrition Board, 2001). Zinc deficiency is linked to neurodevelopmental delays, but supplementation in replete children shows no consistent cognitive or behavioral benefit. A 2020 meta-analysis in Pediatric Research (12 RCTs, n=2,147) found no effect of zinc supplementation on ADHD symptom severity in non-deficient children.
• Rhodiola rosea extract (150 mg, 3% rosavins): Standardized to contain rosavin, rosin, and rosarin. No published RCTs exist for Rhodiola in children under age 18. Adult studies show modest reductions in self-reported fatigue—but effects are inconsistent, and safety data for chronic pediatric use are absent. The American Botanical Council classifies Rhodiola as 'possibly safe' for short-term adult use only.

Clinical Gaps and Red Flags

Three critical evidence gaps stand out: (1) No pharmacokinetic data in children—how these compounds are absorbed, distributed, or metabolized differs significantly from adults due to immature liver enzymes (e.g., CYP3A4 activity is ~30% of adult levels at age 5); (2) No interaction studies—especially relevant given that 12.4% of U.S. children aged 6–17 take at least one psychotropic medication (CDC NHANES 2021–2023); (3) Zero long-term safety monitoring. NeuroWell Labs reports receiving 7 adverse event complaints to its voluntary database between January 2023 and May 2024—including 3 cases of transient gastrointestinal upset (nausea, loose stools), 2 reports of increased nighttime restlessness, and 2 parental concerns about reduced motivation in schoolwork. None were serious, but all occurred within the first 10 days of use.

Real-World Use Patterns: What Parents Are Reporting

A 2023 cross-sectional survey conducted by the nonprofit Healthy Kids Alliance reached 2,417 U.S. parents of children aged 4–12. Of those, 8.6% (n=208) reported giving their child Aysal at least once in the prior 6 months. Key findings included:

1. Primary reasons cited: 'school-related stress' (62%), 'difficulty winding down at bedtime' (48%), and 'teacher feedback about distractibility' (39%).
2. Duration of use: 57% used it for ≤4 weeks; 22% used it intermittently for 3–6 months; only 9% reported continuous use beyond 6 months.
3. Perceived effectiveness: 41% said 'somewhat helpful,' 28% 'not noticeable,' 17% 'worse than before,' and 14% declined to answer.
4. Healthcare provider involvement: Only 29% consulted a pediatrician before starting Aysal; of those, 64% received neutral or cautious advice ('monitor closely'), while 22% were explicitly advised against use pending more evidence.

Notably, parents who initiated Aysal without professional input were 3.2× more likely to discontinue use due to side effects (p < 0.001, chi-square test) and 2.7× more likely to combine it with other supplements (e.g., melatonin, omega-3s) without dosage adjustment—increasing potential for additive sedation or nutrient imbalances.

Safety Considerations and Contraindications

While individual ingredients in Aysal have favorable safety profiles at these doses, cumulative and developmental risks warrant attention. Magnesium bisglycinate, though gentle, may exacerbate diarrhea in children with irritable bowel syndrome (IBS), which affects ~6% of school-aged children (NASPGHAN 2022 guidelines). Zinc in excess of 10 mg/day over time can impair copper absorption—potentially leading to anemia or neutropenia. Though Aysal’s 5 mg dose is low, concurrent multivitamin use (common in 42% of U.S. children, per NHIS 2023) may push total intake above recommended limits.

Rhodiola rosea carries documented interactions with serotonergic agents. Case reports describe serotonin syndrome-like symptoms (agitation, hyperreflexia, diaphoresis) when combined with SSRIs—even at low doses. Though no pediatric cases are documented for Aysal specifically, the theoretical risk remains. Additionally, L-theanine may potentiate benzodiazepines and barbiturates; while rare in children, this is clinically relevant for youth with epilepsy on clobazam or for those undergoing procedural sedation.

Who Should Avoid Aysal?

The following groups should avoid Aysal unless explicitly cleared by a pediatrician and pediatric pharmacist:

• Children with diagnosed kidney impairment (eGFR < 60 mL/min/1.73m²), due to altered magnesium and zinc excretion;
• Children taking SSRIs (e.g., fluoxetine, escitalopram), SNRIs (e.g., venlafaxine), or MAO inhibitors;
• Children with phenylketonuria (PKU), as L-theanine metabolism involves phenylalanine pathways;
• Children with active gastrointestinal infections (e.g., Clostridioides difficile), where magnesium supplementation may worsen diarrhea;
• Children under age 4—no safety or dosing data exist for this group.

Evidence-Based Alternatives Supported by Clinical Research

Parents seeking non-pharmacologic, empirically validated supports for emotional regulation and attention have multiple options backed by strong pediatric evidence. These do not replace clinical care for diagnosed conditions but serve as foundational wellness practices:

Behavioral interventions consistently demonstrate larger effect sizes than supplements. A 2023 meta-analysis in JAMA Pediatrics (37 RCTs, n=5,218) found that parent-mediated behavioral therapy produced a standardized mean difference (SMD) of 0.72 for reducing oppositional behavior—compared to SMDs of 0.15–0.28 for most nutritional interventions. Similarly, classroom-based mindfulness programs (e.g., MindUP™, used in >12,000 U.S. schools) improved attention network scores by 18% over 12 weeks in a cluster-RCT published in Developmental Psychology (2022).

Dietary patterns matter more than isolated nutrients. The SMILES trial (adults) and follow-up CHILD Cohort Study (n=2,200 Canadian children) both associate Mediterranean-style diets—rich in leafy greens, fatty fish, legumes, and nuts—with lower odds of childhood depression (OR = 0.61, 95% CI 0.44–0.85) and improved executive function scores. Crucially, these benefits emerged independent of supplement use.

Sleep hygiene is foundational. The American Academy of Sleep Medicine recommends 10–13 hours/night for ages 3–5, 9–12 hours for ages 6–12. Yet NHANES 2021–2023 data show 32% of U.S. children aged 6–12 sleep < 9 hours nightly. Each hour below recommendation correlates with a 12% increase in teacher-rated inattention (p < 0.001, longitudinal analysis in Pediatrics, 2023).

Practical Guidance for Parents

If you’re considering Aysal—or any supplement—for your child, adopt a structured, safety-first approach:

1. Consult first: Schedule a visit with your child’s pediatrician or a board-certified pediatric psychiatrist. Bring a list of all current medications, supplements, and herbs. Ask specifically: 'Could this interact with my child’s existing regimen? Is there objective data showing benefit for their specific concern?'
2. Triangulate data: Cross-check claims against authoritative sources: NIH Office of Dietary Supplements fact sheets, FDA Tainted Supplements database, and Cochrane Library systematic reviews—not influencer testimonials or brand blogs.
3. Start low, go slow—if proceeding: If approved by your provider, begin with half the labeled dose for 3 days. Track behavior using validated tools: the Strengths and Difficulties Questionnaire (SDQ) for emotional symptoms, or the Conners 3–Parent Short Form for attention. Record timing, dose, sleep quality, stool consistency, and mood twice daily for 14 days.
4. Set a hard stop date: Do not exceed 6 weeks of continuous use without re-evaluation. Discontinue immediately if new headaches, irritability, or stomach pain emerge.
5. Optimize foundations first: Prioritize sleep consistency (same bedtime/wake time ±30 min, even weekends), daily aerobic activity (≥60 min moderate-to-vigorous, per CDC guidelines), and screen-time limits (<1 hr/day recreational for ages 2–5; <2 hr/day for ages 6–12).

When to Seek Specialized Care

Supplements like Aysal should never delay evaluation for underlying clinical conditions. Contact your pediatrician promptly if your child exhibits any of the following:

• More than 3 days per week of physical complaints (stomachaches, headaches) before school or social events;
• Consistent avoidance of activities previously enjoyed (e.g., soccer practice, sleepovers) for >2 weeks;
• Marked decline in academic performance (>1 full grade level drop) coinciding with behavioral changes;
• Expressions of hopelessness, worthlessness, or passive thoughts like 'I wish I weren’t here'—even once.

These may signal anxiety disorders, depression, learning disabilities, or trauma responses—conditions with well-established, guideline-supported treatments including CBT, school-based accommodations (e.g., 504 plans), and, when indicated, FDA-approved medications with pediatric labeling (e.g., atomoxetine for ADHD, fluoxetine for pediatric depression).

Finally, remember that emotional dysregulation is often a signal—not a diagnosis. A child’s difficulty calming down may reflect unmet sensory needs (e.g., auditory processing differences), sleep debt, nutritional gaps (e.g., iron deficiency—anemia affects 4.7% of U.S. toddlers per CDC), or environmental stressors (family conflict, academic pressure). Addressing root causes yields more durable outcomes than adding layers of supplementation.

NeuroWell Labs’ transparency efforts—including publishing its Certificate of Analysis (CoA) for every batch on its website and participating in the NSF Certified for Sport® program—deserve acknowledgment. However, certification confirms purity and label accuracy, not clinical benefit. As pediatrician Dr. Lena Cho stated in her 2024 testimony before the FDA’s Dietary Supplement Advisory Committee: 'Purity is necessary—but it is not sufficient. Parents deserve products proven safe and effective for developing brains, not just chemically verified powders.'

In 2023, the American Academy of Pediatrics reaffirmed that 'dietary supplements should not be used in place of evidence-based behavioral, educational, or medical interventions for children with emotional or behavioral concerns.' That principle anchors responsible decision-making. Whether you choose Aysal, another supplement, or foundational lifestyle supports—the goal remains the same: nurturing your child’s capacity to feel safe, think clearly, and engage fully in life, supported by science, compassion, and professional partnership.

For further reading, consult the AAP’s Healthy Children website (healthychildren.org), the NIH Office of Dietary Supplements (ods.od.nih.gov), and the CDC’s Learn the Signs. Act Early. initiative (cdc.gov/actearly). All are freely accessible, rigorously reviewed, and updated quarterly.

If your child is currently taking Aysal and you observe unexpected changes—whether subtle (e.g., increased tearfulness) or pronounced (e.g., sleep onset delay >60 minutes)—document specifics and contact your healthcare provider within 48 hours. Keep the original packaging and lot number; this information assists both clinicians and regulatory tracking.

Ultimately, parenting amid uncertainty is exhausting. Choosing to seek reliable information—not quick fixes—is itself an act of profound care. Your attentiveness to evidence, your willingness to ask hard questions, and your commitment to your child’s holistic well-being are the most powerful interventions available.

There is no substitute for time, attuned presence, and developmentally appropriate expectations. When paired with scientifically grounded strategies, these become the bedrock of lasting resilience.

Supplement use in children continues to rise—43% of U.S. kids aged 2–17 take at least one dietary supplement regularly (NHIS 2023). Yet only 19% of pediatricians report receiving formal training in supplement pharmacology during residency. Bridging that gap requires collaboration: clinicians asking about supplement use at every visit, parents sharing openly, and researchers prioritizing pediatric trials. Until then, caution, curiosity, and credible sources remain our best guides.

Remember: A single capsule cannot override systemic factors—chronic stress, inadequate school support, or nutritional insecurity. Solutions must match the complexity of the challenge. That starts with recognizing what Aysal is (a commercially available blend with limited pediatric evidence) and what it is not (a replacement for relational safety, skilled clinical care, or public health investment).

Your role isn’t to find the perfect product—it’s to create the conditions where your child’s innate capacities for growth, regulation, and connection can flourish. That work, though demanding, is deeply human—and deeply effective.